Excerpt from a 2011 book:
Ebola Virus (Curable-?, Reversible-?, Preventable?) Due to news coverage in recent years that seems designed to induce fear that a new, uncontrollable killer virus has suddenly appeared, Ebola virus is now generally well-known throughout the world. Ebola is probably the best known of a class of viruses known as hemorrhagic fever viruses. In fact, Ebola virus was initially recognized in 1976. Other less known but related viral syndromes include yellow fever, dengue hemorrhagic fever, Rift Valley fever, Crimean-Congo hemorrhagic fever, Kyasanur Forest disease, Omsk hemorrhagic fever, hemorrhagic fever with renal syndrome, Hantavirus pulmonary syndrome, Venezuelan hemorrhagic fever, Brazilian hemorrhagic fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Lassa fever. The Ebola virus infection, also known as African hemorrhagic fever, has the distinction of having the highest case-fatality rate of the viral infections noted above, ranging from 53% to 88%.
These viral hemorrhagic fever syndromes share certain clinical features. The Cecil Textbook of Medicine notes that these diseases are characterized by capillary fragility, which translates to easy bleeding, that can frequently lead to severe shock and death. These diseases also tend to consume and/or destroy the platelets, which play an integral role in blood clotting. The clinical presentation of these viral diseases is similar to scurvy, which is also characterized by capillary fragility and a tendency to bleed easily. Characteristic skin lesions develop, which are actually multiple tiny areas of bleeding into the skin that surround the hair follicles. some cases even include bleeding into already healed scars. In the classic form of scurvy that evolves very slowly from the gradual depletion of vitamin C body stores, the immune system will be sufficiently compromised for infection to claim the patient’s life before the extensive hemorrhage that occurs after all vitamin C stores have been completely exhausted. Ebola virus and the other viral hemorrhagic fevers are much more likely to cause hemorrhaging before any other fatal infection has a chance to become established. This is because the virus so rapidly and totally metabolizes and consumes all available vitamin C in the bodies of the victims that an advanced stage of scurvy is literally produced after only a few days of the disease. The scurvy is so complete that the blood vessels generally cannot keep from hemorrhaging long enough to allow an infective complication to develop. Also, the viral hemorrhagic fevers typically only take hold and reach epidemic proportions in those populations that would already be expected to have low body stores of vitamin C, such as is found in many of the severely malnourished Africans. In such individuals, an infecting hemorrhagic virus will often wipe out any remaining vitamin C stores before the immune systems can get the upper hand and initiate recovery. When the vitamin C stores are rapidly depleted by large infecting doses of an aggressive virus, the immune system gets similarly depleted and compromised. However, this point is largely academic after hemorrhaging throughout the body has begun.
To date, no viral infection has been demonstrated to be resistant to the proper dosing of vitamin C as classically demonstrated by Klenner. However, not all viruses have been treated with Klenner-sized vitamin C doses, or at least the results have not been published. Ebola viral infection and the other acute viral hemorrhagic fevers appear to be diseases that fall into this category. Because of the seemingly exceptional ability of these viruses to rapidly deplete vitamin C stores, even larger doses of vitamin C would likely be required in order to effectively reverse and eventually cure infections caused by these viruses. Cathcart (1981), who introduced the concept of bowel tolerance to vitamin C discussed earlier, hypothesized that Ebola and the other acute viral hemorrhagic fevers may well require 500,000 mg of vitamin C daily to reach bowel tolerance! Whether this estimate is accurate, it seems clear as evidenced by the scurvy-like clinical manifestations of these infections that vitamin C dosing must be vigorous and given in extremely high doses. If the disease seems to be winning, then even more vitamin C should be given until symptoms begin to lessen. Obviously, these are viral diseases that would absolutely require high doses of vitamin C intravenously as the initial therapy.
The oral administration should begin simultaneously, but the intravenous route should not be abandoned until the clinical response is complete. Death occurs too quickly with the hemorrhagic fevers to be conservative when dosing the vitamin C.
Belfield and Stone (1975) reported enormous success in the treatment of a variety of viral infections in animals, emphasizing that they had found no virus to be unresponsive to intravenous vitamin C. Specifically, with regard to viral diseases, they asserted:
The intravenous use of ascorbate [vitamin C] is especially valuable in the therapy of the viral diseases as it appears to be an effective, non-specific, non-toxic virucidal agent. We have not seen any viral disease that did not respond to this treatment. Successful therapy appears to depend on using it in sufficiently large doses.
The experience of Belfield and Stone with vitamin C and viral infections in animals certainly seems to agree with the phenomenal success that Klenner reported in his treatment of viral infections with vitamin C in humans. It also implies that Ebola viral infection and the other acute viral hemorrhagic fevers should respond to large enough doses of intravenous vitamin C.
Another viral disease that has the capability of producing Ebola-like hemorrhagic complications is smallpox. Akin to chickenpox but much more deadly, smallpox has probably killed approximately 100 million people throughout history. Not surprisingly, smallpox has historically been the most deadly in those populations of people who have the poorest nutritional status and, logically, the lowest body reservoirs of vitamin C. Although no direct evidence of the effects of vitamin C on the smallpox virus could be found in the literature, the virus in the smallpox vaccine is readily killed by vitamin C. This virus, known as the vaccinia virus, is related closely enough to the smallpox virus that inoculation with it will typically produce an immunity to smallpox. However, this fortunate similarity between vaccinia and smallpox virus prevents the need for direct inoculation with some weakened or attenuated form of smallpox virus, eliminating the chance of an accidental smallpox infection. Kligler and Bernkopf (1937) and Turner (1964) found that this related vaccinia virus was easily killed by relatively small amounts of vitamin C. They noted that the degree of viral inactivation depended on the vitamin C concentration and time period it was in contact with the virus. These studies were done shortly after Jungeblut (1935) had demonstrated that vitamin C could similarly inactivate the poliovirus. All of this research represented initial efforts to show the wide-ranging ability of vitamin C to neutralize and/or kill different microbes. Although the vaccinia virus is not the smallpox virus, all of the evidence presented so far would argue strongly that enough vitamin C properly administered should control and cure smallpox as readily as any other of the deadly viral syndromes.
For those who still fear that the Ebola virus is the untreatable disease just waiting to strike down their perfect health, consider the recently published evidence that indicates a symptom-free Ebola infection can and does occur in human beings. Leroy et al. (2000) looked at a number of individuals who were in direct contact with patients sick with Ebola but who had never developed symptoms. Evidence in the blood testing of these patients revealed that a strong inflammatory response early in the course of the infectious process had taken place, and that roughly half of the symptom-free group also developed Ebola virus-specific antibodies. All of this evidence lends further support to the notion that encountering the Ebola virus does not mean instant death. It is also highly unlikely that Ebola virus could successfully sicken an individual with a good general nutritional status, and who is taking a daily bowel tolerance dosage of vitamin C.
Levy MD JD, Thomas E. (2011-08-31). Vitamin C, Infectious Diseases, and Toxins:Curing the Incurable (Kindle Locations 1654-1667). Xlibris. Kindle Edition.
And here is a relevant portion of a 2012 interview with Levy:
Passwater: Is injectable ascorbate available today for U.S. physicians? There was a scare not too long ago that the U.S. Food and Drug Administration (FDA) was preventing the sale of injectable ascorbate.
Levy: It wasn’t a scare. It was quite calculated, and the situation is very serious. Not too long after the airing of Living Proof? on New Zealand’s 60 Minutes program, FDA shut down the mass production of injectable vitamin C by McGuff Pharmaceuticals, which was the company name clearly visible on the vials of vitamin C featured on that program. Since then, FDA has “allowed” vitamin C orders to be separately “formulated” by the McGuff compounding pharmacy, as well as by other compounding pharmacies in the United States. Merit Pharmaceuticals also sells injectable vitamin C, although, to my knowledge, all of that vitamin C is produced by Bioniche Pharmaceuticals in Ireland. All of these “interventions” by FDA have only served to make injectable vitamin C more expensive, which would represent a good initial goal for FDA, as it always appears the agency will do anything to make Big Pharma happier. However, it would still be wonderful if FDA would stop its apparent agenda to ultimately ban vitamin C, although I doubt this is likely. Probably the “best” ultimate outcome will be that vitamin C ends up being available only through prescription. Things are happening very rapidly on this front, and ready access to vitamin C, along with nearly all other supplements, may end as we know it before 2012 is over.
And here is an August 2014 article from Levy: Surprising solution for Ebola virus
And print this for your emergency kit:
The synergistic effect of a multi-C protocol
In most significant chronic diseases, multiple areas of the body have increased oxidative stress and decreased stores of vitamin C and other antioxidants. Since the goal of vitamin C therapy is to neutralize as much oxidative stress and damage as possible, taking as many different types of vitamin C as possible can give the positive clinical results not seen with one, or even two types of vitamin C.
The four main arms of the ‘multi-C protocol are:
1. Liposome-encapsulated vitamin C, 1 to 5 grams orally daily (not homemade formulations)
2. Sodium ascorbate daily up to or reaching bowel tolerance (C-flush)
3. Ascorbyl palmitate, 1 to 3 grams orally daily
4. Intravenous vitamin C (sodium ascorbate or buffered ascorbic acid), 25 to 150 grams, depending on body size. Sometimes daily initially, and often several times weekly to monthly depending upon clinical circumstances
The multi-C protocol is especially effective because:
1. The liposomes put vitamin C inside (intracellular) the diseased cells and the circulating immune cells without the consumption of energy.
2. The oral sodium ascorbate continues to saturate the extracellular areas with vitamin C while neutralizing the toxic products of poor digestion, shared by everyone to a greater or lesser degree.
3. The ascorbyl palmitate gets the normally water-soluble vitamin C into fat-soluble areas.
4. The intravenous vitamin C gets temporarily astronomical blood concentrations of vitamin C throughout the body. – See more at: http://www.naturalhealth365.com/vitamin_c/0929_multi_c_protocol.html#sthash.ZK7o1Z2t.dpuf